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The salivary peptide histatin 5 has been studied as a novel therapeutic to 
address rising drug resistance and limited therapeutics for treating infections caused 
by the fungal pathogen Candida albicans. While histatin 5 possesses antifungal 
activity, degradation from secreted aspartic proteases produced by C. albicans hinders 
its potential. To develop a strategy that will identify variants of histatin 5 with 
improved proteolytic stability, the peptide was integrated into a yeast surface display 
system, and the proteolytic degradation conditions were optimized to improve the 
resolution between proteolytically stable (K11RK17R) and proteolytically susceptible 
(K13L) variants. Additionally, histatin 5 and K11RK17R were embedded in 
polyelectrolyte multilayer films (PEMs) to investigate their ability to prevent biofilm 
formation on surfaces. Significant biofilm formation was prevented at high 
  
concentrations of K11RK17R, while histatin 5 encouraged biofilm formation. My 
results support the therapeutic potential of histatin 5 and will enable the design of 
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Chapter 1: Introduction 
 
1.1 Clinical Relevance of C. albicans 
Candida albicans is a fungal pathogen within the Candida genus of 
ubiquitous, yeasts that are naturally associated with the flora of the skin, intestinal 
tract, and genitourinary tract of healthy individuals [1]. Commensal in nature, C. 
albicans lives within these microbiomes along with other Candida species without 
harm until an individual’s immunity is compromised and the risk of opportunistic 
infection increases. Candida can then reversibly transition from a yeast to hyphal 
state (Figure 1.1) [2]. In hyphal form, C. albicans can invade local tissue and colonize 
the surfaces of medical devices such as implants, dentures, and catheters, causing a 
range of responses from minor candidemia symptoms to severe sepsis [3]. C. albicans 
is the most prevalent species of Candida in these infections, which is attributed to its 
high adaptability to stressful and unfavorable environments [3, 4]. With this in mind, 
C. albicans represents a significant health risk to those undergoing chemotherapy [5], 
recipients of solid-organ transplants [6] or hematopoietic stem cell transplants 
(HSCTs) [7], and individuals with diabetes [8], HIV/AIDS infections [9], and 
pregnant women [10]. Additionally, contraction of a C. albicans infection can pose a 
significant financial burden on patients as adequate treatment can result in an average 
increase in total hospital charges and cost of hospitalization by $6,000-$29,000 and 





treatment options for these infections is fortunately well established and can be 




Figure 1.1: Yeast and Hyphal States of C. albicans. Figure modified from reference 
[2]. Used with permission. Yeast form of C. albicans is shown in the left-most panel 
followed by developing stages of hyphal formation in the remaining panels (left to 
right). Scale bar represents 5 µm.  
 
To treat C. albicans infections, echinocandins (caspofungin and micafungin) 
are currently used for primary treatment with high survival rates [3, 12]. This class of 
small molecule drugs target C. albicans by inhibiting the synthesis of b-(1,3)-glucan, 
a major structural component of the fungal cell wall, and compromise the structural 
integrity of the cell [13]. However, repeat treatment with this class of therapeutics has 
resulted in the emergence of echinocandin-resistant C. albicans, which gain resistance 
through the upregulation of chitin synthesis to repair damage caused by 
echinocandins and strengthen the cell wall [13]. The emergence of echinocandin-
resistant C. albicans was first reported in 2005 and continues to rise, currently 
comprising 2-3% of all C. albicans infections with approximately 36% of them 
displaying resistance towards azoles as well [14].  
Azoles (fluconazole, itraconazole, and voriconazole) are another class of 





secondary (i.e. step-down) treatment for both topical and systemic C. albicans 
infections [3, 12, 15]. While there are differing opinions as to whether echinocandins 
or azoles are better for treatment, the azoles are more commonly used due to their 
highly demonstrated efficacy [3, 15], low cost [16], and more convenient and 
adaptable dosing regimen, which ensures higher patient compliance [15]. Similar to 
echinocandins, this class of therapeutics target C. albicans by inhibiting the synthesis 
of the sterol ergosterol. Azoles inhibit 14a-demethylase encoded by the gene ERG11 
[16]. Therefore, it is not surprising that azole-resistant C. albicans strains have also 
emerged, utilizing efflux pumps, mutations in the ERG11 gene, and development of 
bypass signaling pathways to overcome the stress imparted by azoles [17]. The heavy 
reliance on this class of therapeutics and high incidence of resistant isolates has made 
azole-resistant C. albicans a serious threat to public health, making it onto the report 
of antibiotic resistance threats published by the Centers for Disease Control and 
Prevention in 2013 [18]. In these cases, where azole and echinocandin resistance are 
observed, amphotericin B is often utilized to treat these persistent infections.     
Amphotericin B is a third, potent treatment option used for secondary 
treatment of C. albicans infections or primary treatment in low resource areas [12]. 
Amphotericin B targets C. albicans by selectively binding to ergosterol in the cell 
membrane and inducing pore formation followed by rapid cell death [19]. Isolates of 
C. albicans that are resistant to amphotericin B have been reported in select cases, 
and resistance occurs when the cell turn off the production of C-5 sterol desaturase 
and lanosterol 14a-demethylase through ERG3 and ERG11, respectively, leading to 





resistance has remained stagnant over the past 50 years [19, 20]. Therefore, 
amphotericin B represents a promising therapeutic for the continued treatment of 
drug-resistant C. albicans. However, the reason this drug is not used in primary 
treatment is because of its inherent kidney toxicity [19, 21, 22, 23]. Combinatorial 
therapy of amphotericin B and fluconazole have been shown to reduce kidney toxicity 
with efficacious performance against azole-resistant C. albicans [21]. Additionally, 
lipid (Abelcet) and liposomal (AmBisome) formulations of amphotericin B have been 
shown to reduce these toxic side effects and increase its safety profile [22, 23]. 
However, the high cost of these formulations is responsible for their low utility in the 
clinical setting [24]. With this in mind, reduced sensitivity to amphotericin B remains 
difficult to treat and is also becoming more of an issue in Candida infections caused 
by non-albicans species.   
In addition to C. albicans, the rise of international, multi-drug resistance has 
also been documented in C. auris [25, 26, 27] and C. glabrata [26] with alarming 
global incidence. In both cases, multiple incidence of fluconazole resistant strains has 
been reported with variable sensitivity to echinocandins, azoles, and amphotericin B, 
which make them difficult to treat [26, 27]. Furthermore, both inter- and intra-
transmission of multi-drug resistant C. auris infections have been denoted, giving rise 
to its spread amongst patients [25, 27]. With this in mind, there is a demand for novel 
therapeutics that can expand the currently limited arsenal of treatment options and 
address the growing presence of multi-drug resistant strains of C. albicans and 





1.2 Novel Antifungal Therapeutics 
Given the growing presence of fluconazole-resistant C. albicans as well as 
multi-drug resistant strains, novel therapeutics and strategies are required to contain 
these threats and support the treatment of these infections when current methods fail. 
In response to this, antifungal peptides represent an advantageous alternative due to 
their consistently high levels of safety, tolerance, and efficacy, which distinguishes 
them from small molecule drug alternatives [28]. Additionally, due to the natural 
origin of these therapeutics, antifungal peptides enjoy an inherently selective mode of 
antifungal/bacterial action, making them great platforms for therapeutics [29]. The 
threat of drug-resistance to this class of therapeutics is also less than that for small 
molecules as their rapid fungicidal activity and cell-wall specificity minimizes the 
opportunity for adaptation [30]. However, antifungal peptides, as well as other 
peptide therapeutics, are currently significantly more expensive to manufacture 
compared to the small molecule drugs currently utilized, preventing them from 
becoming widely used in the clinic [31]. For example, it is generally estimated that 
the production cost of a 5 kDa peptide will exceed the production of a 500 Da small 
molecule by more than 10-fold assuming the peptide is produced via solid-phase 
synthesis, which is currently the most mature form of technology for the production 
of peptides [31]. Despite this fact, antifungal peptides remain an important area for 
therapeutic development due to their promising safety profile, lack of off-target 
binding, and flexible pharmacokinetic profile, which can be adjusted with protein 





studied, one that has received noticeable attention with regards to therapeutic 
development is histatin 5.  
 Histatin 5 is a natural, histidine-rich, cationic, salivary peptide part of the 
innate immune system with strong antifungal activity for C. albicans and other 
foreign microbes [33]. A member of a larger family of histatin peptides secreted from 
the human parotid gland, histatin 5 is 24 amino acids long and exhibits the highest 
fungicidal activity against C. albicans of the histatins [34]. Unlike many antifungal 
peptides, which target the cell wall and cause pore formation to induce cell death, 
histatin 5 binds to the cell wall protein and glycans and utilizing influx pumps, Dur3 
and Dur31, to traverse the cell membrane [33, 35], which is illustrated in Figure 1.2. 
Inside, reactive oxygen species (ROS) are generated by histatin 5 in the mitochondria, 
leading to stress response and rapid cell death [33, 35]. In response to this, C. 
albicans has been reported to reduce the cytosolic concentration of histatin 5 by 
removing the peptide through the efflux pump Flu-1 as a means of resistance [35, 36, 
37]. Fortunately, this phenomenon has been limited to Flu-1 and associated efflux 
pumps and has not been observed through mutations or down regulation of Dur3 or 
Dur31, which is most likely due to the pathogen’s reliance on these pumps for 
viability and their unique role in polyamine intake [37, 38, 39]. Despite this 
mechanism of natural resistance, histatin 5 has significant fungicidal activity for C. 
albicans and has been demonstrated as a promising therapeutic to treat vulvovaginal 
candidiasis [40], prevent C. albicans proliferation in a variety of pHs and ionic 








Figure 1.2: Transport of Histatin 5 into C. albicans. This figure was acquired from 
reference [35]. Used with permission. In this diagram, histatin 5 (orange cylinders) is 
shown entering the cytosol through the transmembrane Dur3/31 influx pumps and 
generating ROS species in the mitochondria. The efflux pump Flu1 is also shown 
releasing histatin 5 into the extracellular space.  
 
 Histatin 5 is also highly explored as a novel therapeutic because of its ability 
to reduce the pathogen’s virulence factors: filamentation and biofilm formation [43]. 
This phenomenon is attributed to histatin 5’s generation of stress response in C. 
albicans, which subsequentially reduces the hyphal growth and biofilm development 
through environmental signaling pathways [44]. Inhibiting biofilm formation is 
advantageous as it prevents infection as well as the colonization of C. albicans to 
medical devices [45]. Given this behavior, C. albicans is not likely to develop 
additional resistance to histatin 5, as the low doses required to prevent filamentation 
do not significantly challenge the viability of the cell [24, 46]. However, one 





therapeutic index of histatin 5, are the secreted aspartic proteases (Saps) naturally 
generated by C. albicans which can degrade the peptide into less potent fragments. 
1.3 Secreted Aspartic Proteases (Saps) Expressed by C. albicans 
To aid in its virulence, C. albicans secretes a family of ten secreted aspartic 
proteases (Saps) that assist with infection by degrading cell surfaces and host immune 
proteins [47]. Among these ten aspartic proteases, Sap1 through Sap8 are fully 
secreted to the extracellular environment while Sap9 and Sap10 are anchored to the 
cell wall through a GPI-anchor or GPI proteins [48, 49]. The expression of each Sap 
is dependent upon the environmental conditions, such as local pH and the type of 
local tissue, and the morphological state of the cell [49]. For example, Sap1 through 
Sap3 are primarily expressed in the yeast cell state while Sap4 through Sap6 are more 
prevalent in its hyphal form in oral candidiasis [49]. Meanwhile, in the case of 
vulvovaginal candidiasis, Sap2 Sap9, and Sap10 are initially observed followed by 
Sap1, Sap4, and Sap5 in early stages of infection and Sap6 and Sap7 in later stages 
[49]. In both cases of oral and vulvovaginal candidiasis, Sap2, Sap5, Sap9, and Sap10 
remains the most highly expressed protease [50]. Therefore, a host of possible SAPs 
are available for the degradation of endogenous and therapeutic antifungal peptides, 
which can limit the therapeutic potential of peptide-based antifungal agents.    
 The SAPs expressed by C. albicans possess a diverse range of substrate 
specificities, presenting a potent cocktail for the degradation of local proteins and 
peptides [51]. Sap1 through Sap6 and Sap8 preferentially degrade at positively 
charged (Arg and Lys) and large hydrophobic (Leu, Phe, and Tyr) amino acids while 





possess a global specificity for Ala at the amino acid located directedly downstream 
of the primary amino acid site with the exception of Sap6, which prefers Tyr [52]. 
Therefore, designing therapeutic agents that are completely resistant to proteolytic 
degradation from all Saps can be a difficult task. An easier alternative involves 
identifying Saps with the most significant substrate activity or opportunity for 
degradation and engineering the peptide for high proteolytic stability with respect to 
these Saps. As a starting point, the degradation activity of Sap2 and Sap9 was 
investigated on histatin 5 due to their overall high expression and broadly covered 
specificity [53].  
1.4 Prior Efforts to Increase the Proteolytic Stability of Histatin 5 
Given that histatin 5 was significantly degraded by Sap2 (40% degraded) and 
Sap9 (60% degraded) [53], and both Saps possess promiscuous specificity [51], 
mutations were investigated for their ability to impact proteolytic stability [53]. The 
primary residues that were investigated were lysines due to an observed preference 
for cleaving this amino acid in histatin 5 [54]. Each of the lysines was substituted 
with either arginine or lysine [53]. From proteolytic degradation assays, the mutation 
K17R significantly increased the proteolytic stability and K13L decreased the 
proteolytic stability [53]. Most importantly, these mutations did not reduce the 
antifungal activity of the peptide. A double mutant, K11RK17R, was also found to 
further improve the proteolytic stability of histatin 5 beyond that imparted by each 
individual mutation [55]. Given these significant improvements, it begs the question 
that other sites can be explored and if further improvement can be imparted with other 





1.5 Directed Evolution as an Approach to Identify Variants with High Proteolytic 
Stability 
Directed evolution, which mimics the process of natural selection, is an 
important approach used to improve the fitness properties of proteins and peptides for 
therapeutic applications. This involves introducing random variation throughout the 
gene for the peptide or protein of interest and subjecting the library to successive 
rounds of screening and mutagenesis, where a promising mutant or mutants isolated 
from a given round are used as the foundation for mutagenesis in the next round [56]. 
Iterations continue until a mutant(s) with the desired fitness for a desired property are 
identified [57].  
This approach has been validated through the screening of mutations in the 
PK15 bicyclic peptide with improved inhibition of the intestinal protease plasma 
kallikrein (hPK), which degrades therapeutic peptides in this region [58]. Applying 
directed evolution through phage surface display, potent inhibitors were identified 
with inhibitory concentrations in the nM range with a consensus Xaa-Pro motif [58]. 
Additionally, directed evolution can be used to identify sites of preferential 
degradation, helping guide the usage of site-mutations to improve fitness. For 
example, McGlinchey et al. used directed evolution to elucidate the role of different 
cysteine cathepsins in the degradation of α-synuclein, a peptide associated with 
Parkinson’s disease [59]. From these studies, significant degradation was observed 
with different cathepsins at different sites, allowing for the substrate specificity to be 
mapped [59]. With this in mind, random mutations could be implemented into histatin 





1.6 Overview of Thesis 
This thesis describes the work to optimize a yeast surface display system for 
histatin 5 to enable the effective screening of novel mutants for improved proteolytic 
stability and also investigates the potential of histatin 5 and K11RK17R to be coated 
on medical devices with polyelectrolyte multilayer films (PEMs) to treat oral 
candidiasis. In Chapter 2, histatin 5 and the variants K11RK17R and K13L are 
integrated into a yeast surface display platform and the degradation conditions are 
optimized to improve the resolution between proteolytically stable and susceptible 
peptides to assist in the future screening of a novel peptide library for improved 
proteolytic stability. In Chapter 3, a study is performed to investigate the potential for 
histatin 5 and K11RK17R to be incorporated into a surface coating for medical 
devices for the treatment of oral candidiasis. Finally, my conclusions and 










Chapter 2: Engineering Enhanced Proteolytic Stability in 




Yeast surface display is a cell surface display system developed in 
Saccharomyces cerevisiae that allows for the easy screening of a protein library for 
improved fitness properties. Initially designed by Boder and Wittrup in 1997 for the 
evolution of a human single-chain variable fragment (scFv) with improved binding 
affinity for its antigen (FITC-dextran) [60], this system represents a promising 
method for the protein engineering of mammalian and eukaryotic proteins. In yeast 
surface display, the protein of interest (POI) is targeted to the extracellular space as a 
part of a fusion to the cell wall by the cell-cell adhesions protein a-agglutinin 2 
(Aga2) (Figure 2.1). Aga2 establishes a physical linkage to the cell wall with the help 
of a-agglutinin 1 (Aga1). Aga1 is covalently linked to 1,6-b-glucans in the yeast cell 
wall and Aga2 is connected to Aga1 by reduceable, disulfide bridges [60]. In the 
Aga2-POI fusion, the POI is covalently sandwiched between an upstream 
hemagglutinin antigen (HA) and downstream C-Myc epitope tags for quantification 
of display [60]. With this design, the phenotypic properties of the protein of interest 
can be physically traced back to the gene that produced it, providing the phenotype-








Figure 2.1: Schematic Illustration of Yeast Surface Display in Yeast. A terminal 
10-residue epitope tag (C-Myc) is fused to the c-terminus of the protein of interest 
(POI), allowing detection of the whole fusion display. A flexible polyglycine-serine 
linker (G4S)3 covalently links the POI to the 9-residue HA epitope tag, allowing 
detection of the fusion display in the case of POI degradation. Upstream, the Aga2 
protein subunit of a-agglutinin is bound to the Aga1 protein subunit through two 
disulfide bridges, anchoring the fusion protein to the cell wall. 
 
Compared to other cell surface display methods such as bacterial and phage, 
yeast surface display possesses a competitive advantage given the larger size of the 
yeast cell (5-10 µm) compared to that of E. coli (1 µm) and phage (20-200 nm). This 
allows yeast to express significantly more fusion proteins (approximately 1 x 104 – 1 
x 105 fusions/cell), ensuring sufficient access for interrogation of the desired property 
[60, 62]. In terms of the library size, yeast surface display is able to accommodate 














only dwarfed by in vitro ribosome and mRNA screening platforms due to the 
transformation limitation needed to introduce the gene of interest into the yeast cells 
[62, 63]. While not relevant to work with histatin 5, it is also worth mentioning that 
yeast surface display is capable of expressing mammalian proteins with correct post-
translational modifications and glycosylation patterns, allowing it to be used for the 
development of mammalian proteins and antibody domains [62]. 
Given the numerous advantages present in yeast surface display, this 
technology has been utilized in several different applications since its genesis, 
including epitope mapping [64, 65], cell adhesion engineering [65], and the 
identification of protein-protein interactions [64]. Additionally, in terms of proteolytic 
applications, yeast surface display has been used to map substrate selectivity of the 
tobacco etch virus protease and enhance the selectivity by 5,000 – 10,000-fold [64] 
and to develop potent protease inhibitors for human tissue kallikrein proteases [66] 
and trypsin [67]. Furthermore, yeast surface display has improved the proteolytic 
stability of the human amyloid precursor protein Kunitz protease inhibitor domain 
(APPI) in the presence of mesotrypsin, increasing its proteolytic stability by 83-fold 
[68]. With this in mind, yeast surface display is a promising tool that can be used to 





2.2 Materials and Methods 
2.2.1 Peptides 
The peptides utilized in this chapter can be found in Table 2.1 and were 
incorporated into the yeast surface display fusion using primers (Table 2.2), as 
described in section 2.2.3. 
Table 2.1: Peptides Integrated into Yeast Surface Display 




Histatin 5 D S H A K R H H G Y K R K F H E K H H S H R G Y 3036 +12 
K11RK17R - - - - - - - - - - R - - - - - R - - - - - - - 3092 +12 
K13L - - - - - - - - - - - - R - - - - - - - - - - - 3021 +11 
*Dashes indicate unchanged amino acids previously found in parent peptide.  
**Net charge (pH 7.0) is calculated only from the amino acid side chains and does 
not include the N-terminal amine.   
2.2.2 Strains and Culture Conditions 
The S. cerevisiae strain EBY100 was purchased from the American Type 
Culture Collection (ATCC). Cells were first inoculated from a synthetic dextrose-
casamino acids (SD-CAA) yeast minimal media (20g/L dextrose, 6.7 g/L yeast 
nitrogen base, 5.0 g/L casamino acids, 5.4 g/L Na2HPO4, 8.56 g/L NaH2PO4×H2O, 
182 g/L sorbitol, pH 6.0) agar plate into 7.5 mL of  SD-CAA media (20g/L dextrose, 
6.7 g/L yeast nitrogen base, 5.0 g/L casamino acids, 10.4 g/L sodium citrate, 7.4 g/L 
citric acid monohydrate, pH 4.5) and grown overnight (»24 h) at 30°C while shaking 
at 230 rpm. The overnight cell culture was subsequentially subcultured into 7.5 mL of 
fresh SD-CAA media (20g/L dextrose, 6.7 g/L yeast nitrogen base, 5.0 g/L casamino 
acids, 10.4 g/L sodium citrate, 7.4 g/L citric acid monohydrate, pH 4.5) at a starting 





grown at 30°C while shaking at 230 rpm until the OD600 reached 2.0-3.0 (»8-10 h). 
The cell culture was centrifuged at 3,000 x g for 5 min at 4°C, and the spent media 
was discarded. The cell pellet was resuspended in 50 mL yeast minimal expression 
media SG-CAA + 2% dextrose (20g/L galactose, 0.2 g/L dextrose, 6.7 g/L yeast 
nitrogen base, 5.0 g/L casamino acids, 10.4 g/L sodium citrate, 7.4 g/L citric acid 
monohydrate, pH 4.5) and allowed to incubate at 30°C while shaking at 230 rpm until 
the appropriate time point was reached. 
2.2.3 Plasmid Construction 
Plasmids containing the yeast surface display fusion protein were constructed 
using the pCTcon2-scFv-F4 plasmid [69], which is shown in Figure 2.2. This plasmid 
possesses a divergent galactose inducible promoter (GAL1,10) for the controlled 
expression of the surface display fusion. Additionally, pCTcon2-scFv-F4 incorporates 
an ampicillin resistance gene (AmpR) for easy viability selection during recombinant 
cloning and a phosphoribosylanthranilate isomerase gene for tryptophan biosynthesis 
(TRP1) for viability selection in tryptophan-deficient media. All peptides were 
genetically incorporated into the fusion protein using the primers provided in Table 
2.2.  
For the DNA encoding histatin 5, the primer pair NheI-Hst5-Top1 and Nhe-
Hst5-Bot1 and the primer pair BamHI-Hst5-Top2 and BamHI-Hst5-Bot2 were 5’ 
phosphorylated and annealed to create Hst5(1) and Hst5(2) respectively. The 
annealed Hst5(1) had a 5’ NheI sticky end and the annealed Hst5(2) had a 3’ BamHI 
sticky end; Hst5(1) and Hst5(2) had complementary sticky ends as well, allowing 





the NheI and BamHI cut sites to replace the DNA encoding scFv F4 in the source 
plasmid and generate pCTcon2-Hst5. Similarly, for the DNA encoding K11RK17R, 
the primer pair NheI-K11R-Top1 and NheI-K11R-Bot1 and the primer pair BamHI-
K17R-Top1 and BamHI-K17R-Bot1 were 5’ phosphorylated and annealed to create 
K11R(1) and K17R(2) respectively. The annealed K11R(1) had a 5’ NheI sticky end 
and the annealed K17R(2) had a 3’ BamHI sticky end; K11R(1) and K17R(2) had 
complementary sticky ends as well, allowing them to anneal together. The two pairs 
were inserted into pCTcon2 between the NheI and BamHI cut sites to replace the 
DNA encoding scFv F4 in the source plasmid and generate pCTcon2-K11RK17R. 
Similarly, for the DNA encoding K13L, the primer pair NheI-K13L-Top1 and NheI-
K13L-Bot1 and the primer pair BamHI-Hst5-Top1 and BamHI-Hst5-Bot1 were 5’ 
phosphorylated and annealed to create K13L(1) and Hst5(2) respectively. The 
annealed K13L(1) had a 5’ NheI sticky end and the annealed Hst5(2) had a 3’ BamHI 
sticky end; K11R(1) and K17R(2) had complementary sticky ends as well, allowing 
them to anneal together. The two pairs were inserted into pCTcon2 between the NheI 
and BamHI cut sites to replace the DNA encoding scFv-F4 in the source plasmid and 








Figure 2.2: Illustration of pCTcon2-scFv-F4. Figure obtained from reference [69]. 
Expression of TRP1 and AmpR genes are regulated by the TRP1 and AmpR 
promoters, respectively. Expression of the yeast surface display fusion protein (Aga2-
HA-POI-Myc) is regulated by the GAL1, 10 promoter. In this plasmid, the POI is the 
scFv-F4, which is flanked on either side by the restriction enzyme sites NheI and 
BamHI for easy substitution.  
 
Table 2.2: Primers Used for Construction of pCTcon2 Plasmids 



































All plasmids were Sanger sequenced using the primers Forward-Seq-pCTcon2 
and Reverse-Seq-pCTcon2 to confirm the correct construction of each construct. All 
plasmids were chemically transformed into S. cerevisiae strain EBY100 using the EZ 
Yeast Transformation II Kit (Zymo Research). 
2.2.4 Western Blotting 
Western blotting was performed by first harvesting a 50 mL expression 
culture of EBY100 cells transformed with the appropriate plasmids after 22 hours of 
incubation at 30°C while shaking at 230 rpm. Cells were initially centrifuged at 3,000 
x g for 5 min at 4°C and the liquid was discarded. The cell pellet was resuspended in 
yeast protein extraction reagent (Y-PER, Thermo Scientific) to a concentration of 385 
mg/mL and mixed on a microplate shaker (VWR) at 250 rpm for 20 min at room 
temperature. The cell solution was centrifuged at 14,000 x g for 10 min and the liquid 
portion was decanted as the “soluble protein fraction.” The remaining cell pellet was 
resuspended in 150 µl of 8 M urea and was mixed for 20 min at room temperature 
prior to centrifugation at 11,000 x g for 15 min. The supernatant was decanted as the 
“insoluble protein fraction.” 
The fractions were adjusted to approximately equal protein concentrations, 
and each fraction was were mixed in 1:1 proportion with a 2X SDS+b-
mercaptoethanol solution (95% (v/v) 2X SDS loading dye, 5% (v/v) b-
mercaptoethanol) and were boiled at 98°C for 5 min before being loaded onto and run 
on a mini-PROTEIN® TGX precast gel (Bio-Rad) for 25 min at 200 V. The 





using the Trans-Blot® Turbo Transfer System (Bio-Rad) at 1 A, 25 V for 30 min. 
After transfer, the membrane was blocked with 5% (w/v) nonfat dry milk in Tris-
buffered saline with Tween (TBST) (2.4 g/L Tris-HCl, 0.56 g/L Tris-base, 8.8g/L 
NaCl, 0.1% (v/v) Tween-20) for 1 h at room temperature and 230 rpm. The 
membrane was washed twice for 10 min with TBST and was incubated with the 
appropriate antibodies for 1 h to detect the epitope tags. The HA tag was detected 
with the primary anti-HA tag antibody (ab130275, Abcam) at 1:1,000 dilution in 
TBST followed by secondary rabbit anti-mouse IgG H+L antibody (HRP) (ab6728, 
Abcam) at 1:5,000 dilution in TBST. The C-Myc tag was detected with the anti-Myc 
tag antibody (HRP) (ab1326, Abcam) at 1:5,000 in TBST dilution. Six washes with 
TBST were performed between primary and secondary antibodies for HA detection. 
Both membranes were washed three times with TBST after labelling with HRP 
conjugated antibodies followed by one wash with Tris-buffer saline (TBS) (2.4 g/L 
Tris-HCl, 0.56 g/L Tris-base, 8.8g/L NaCl, pH 7.6). Clarity Western ECL Substrate 
(Bio-Rad) was used as the substrate for HRP, and membranes were imaged using a 
ChemiDoc MP imaging system (Bio-Rad). 
2.2.5 Secreted Aspartic Proteases (Saps) 
The secreted aspartic proteases (Saps) 2 and 9 were provided by Dr. Bernhard 
Hube from Friedrich Schiller University, Germany. The Saps were expressed in 





2.2.6 Degradation of Expressed Fusion Peptides 
After expression, the OD600 of the cell culture was measured and 4 x 106 cells 
were aliquoted and placed on ice. Cells were centrifuged at 16,000 x g for 1 min and 
liquid was removed. Cell pellets were washed three times with 1 mM sodium 
phosphate buffer (NaPB) (0.155 g/L NaH2PO4 • 7 H2O, 0.058 g/L Na2HPO4 • H2O, 
pH 7.0) for degradation by Sap2 or Sap9. Cells were resuspended in 0.1 mL of 1 mM 
NaPB, Saps were added to the desired concentration, and samples were placed at 
30°C on a microcentrifuge tube rotator (VWR) to avoid cell precipitation. As a 
control, a separate aliquot of cells was washed three times with ice-cold PBS (8 g/L 
NaCl, 0.2 g/L KCL, 1.44 g/L Na2HPO4, 0.24 g/L KH2PO4, pH 7.4) and was 
immediately labelled with antibodies for flow cytometry or fluorescent-activated cell 
sorting (FACS) analysis.   
2.2.7 Preparation for Flow Cytometry and FACS 
After incubation, cells were centrifuged at 16,000 × g for 1 min and the liquid 
was discarded. Cell pellets were washed three times with ice-cold PBS and were 
resuspended in 0.1 mL ice-cold PBS. Approximately 5 x 105 cells were retained for 
viability assessment. Primary antibodies anti-HA tag (ab130275, Abcam) and chicken 
anti-c-Myc epitope tag (ACMYC, Gallus) were added in 1:200 dilution and cells 
were incubated at 4°C on a microcentrifuge tube rotator for 30 min. Cells were 
centrifuged at 16,000 x g for 1 min, and liquid was discarded. The cell pellet was 
washed three times with ice-cold PBS and was resuspended in 0.1 mL ice-cold PBS. 
Secondary antibodies Alexa Flour 488 goat anti-mouse IgG H+L (A11029, Life 





Technologies) were added in 1:50 dilution, and cells were incubated at 4°C on the 
microcentrifuge tube rotator for 45 min while wrapped in foil to avoid light exposure. 
Cells were centrifuged at 16,000 x g for 1 min in minimal lighting and liquid was 
discarded. Cell pellets were washed three times with ice-cold PBS and were 
resuspended to 5 x 105 cells/mL in ice-cold PBS for flow cytometry or FACS 
analysis. 
2.2.8 Sap Degradation Analysis 
Degradation was assessed with flow cytometry (BD FACSCanto II), and data 
was analyzed using FlowJo software. For the analysis, an unlabeled cell control was 
used to establish the gating scheme for the samples analyzed in a given set of 
experiments. Gating of the cell control involved first isolating events measured during 
homogenous flow through the detector, followed by the isolation of single, live cells 
using the forward and side scatter filters. Events were plotted on a bivariate log-log 
plot of signals with Alexa-Flour 488 (corresponding to the labeling of the HA epitope 
tag) and APC (corresponding to the labeling of the C-Myc epitope tag) filters and 
quadrants were drawn to gate the entirety of the cell control in Q4. An identical 
gating scheme was applied to all related samples. The percent of events and both the 
means and standard deviations of both signals in each quadrant were recorded and 
used for statistical analysis (GraphPad Prism 8.01).  
2.2.9 Cell Viability Analysis 
Viability was assessed after incubation with Saps to evaluate the influence of 





x 105 cells was diluted in PBS to a final concentration of 2.5 x 103 cell/mL, and 40 µl 
was spread on three YPD agar (10 g/L yeast extract, 20 g/L peptone, 20 g/L glucose, 
2% (w/v) agar) plates. The plates were incubated at 30°C for 48 hours, and colonies 
were counted to determine the colony forming units (CFU) per mL for a given sample 
(n=3).  
2.3 Results 
2.3.1 Scope of Research 
The incorporation of histatin 5, K11RK17R, and K13L into yeast surface 
display was performed to assess the utility of this system to screen for variants with 
enhanced proteolytic stability in the presence of Sap2 and Sap9. The role of pH, 
protease concentration, temperature, and time on the degradation of histatin 5 were 
investigated to identify optimal degradation conditions to be used for the 
interrogation of a future peptide library designed from histatin 5.  
2.3.2 Validation of Fusion Expression by Western Blotting 
Western blotting was performed to validate the expression of the full yeast 
surface display fusion protein generated by pCTcon2-Hst5 and the original plasmid 
pCTcon2-scFv-F4 in both soluble and insoluble protein fractions (Figure 2.3). 
Validation was performed by blotting for both HA and C-Myc epitope tags in both 












Figure 2.3: Western Blot of Aga2-Histatin 5 and Aga2-scFv-F4 Using pCTcon2 
Plasmid. Detection of M-Myc and HA epitope tags are shown with the standard 
protein sizes determined from molecular weight ladder. EBY100 cells without either 
plasmid was run as a control along with fractions for Aga2-ScFv-F4 (scFv) and 
Aga2-histatin 5 (Hst5). The expected weights of Aga2-scFv-F4 and Aga2-Hst5 were 
approximately 42.7 kDa and 17.5 kDa, respectively. 
 
Bands were observed for Aga2-scFv-F4 and Aga2-histatin 5 at approximately 
53 kDa and 35 kDa, respectively for both C-Myc and HA epitope tag detection. 
While both bands are slightly larger in molecular weight than their expected band 
sizes, the displacement is uniform and is not uncommon to observe in Western 
blotting. The presence of a second degradation product band was also observed in the 
insoluble fraction of Aga2-histatin 5, which is occasionally observed in Western 
blotting. This validated the expression of the entire fusion in both cases as the 
presence of both epitope tags were detectable in the same band corresponding to the 
size of the whole protein fusion.   
2.3.3 Optimizing Expression of Yeast Surface Display Fusion Protein 
Expression optimization was initially performed with the plasmid pCTcon2-
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cell while only labeling for the C-Myc epitope tag, indicating the presence of the full 
protein fusion. The goal was to determine the optimal conditions required to obtain 
the highest number of fusion proteins expressed per cell, ensuring easy interrogation 
of the expressed fusion protein in later proteolytic degradation assays. Expression was 
performed at both 30°C, which was recommended by the Boder and Wittrup [60], and 
20°C, which was shown to be the optimal conditions for total mammalian protein 
expression in S. cerevisiae [72], for 6, 10, 14, 18, 22, and 26 h. For all samples, 4 x 
106 cells were aliquoted and only labelled with an anti-c-Myc antibody, which would 
indicate the presence rest of the entire fusion construct. Cells expressing the full 
fusion were identified using a Myc+/Myc- gate calibrated from an unlabeled cell 
control and are shown in Figure 2.4.  
 
Figure 2.4: Fusion Protein Expression as a Function of Time and Temperature. 
All presented data correspond to the average of the percent of positively expressing 
cells based on two independent biological replicates (n=2) with error bars 
representing the standard deviation in the population. Expression of full construct was 
quantified by flow cytometry with an Alexa-Flour 647 goat antibody to detect the 
displayed construct. The number of asterisks indicates the level of significance: * for 
P<0.1, ** for P<0.01, and *** for P<0.001; ns indicates not significant). 


































Significantly higher levels of fusion expression per 4 x 106 cells were observed at 
30°C compared to 20°C for all time points with the exception of 22 and 26 h. No 
significant difference was observed between all expressions performed at 30°C. 
Therefore, expression was conducted for 14 – 16 h for all future assays due to the 
high levels of accomplished expression and convenience.    
2.3.4 Initial Degradation Profiles of Displayed Peptides 
Prior to using yeast surface display to generate and screen a library of variants 
for improved proteolytic stability, initial degradation profiles were gathered to assess 
how distinguishable protease resistant (K11RK17R) and proteases susceptible (K13L) 
variants would be without optimization of degradation conditions. Therefore, an 
initial incubation of both variants displayed on the surface of yeast cells was 
performed for 2 h at 30°C with 200 µg/mL of both Sap2 and Sap9 with 4 x 106 cells 
in 1 mM NaPB. Flow cytometric analysis was performed on the resulting samples 













Figure 2.5: Initial Degradation Profiles of K11RK17R and K13L. Bivariate plots 
of the intensity for both HA (Alexa-Flour 488 antibody) and C-Myc (Alexa-Flour 647 
antibody) were plotted with quadrants based on cell standards for both plasmids. Each 
dot corresponds to a single cell and density of cells is indicated by heat map. 
Numbers located in the corner of each quadrant represent the percent of total events 
located within each boundary. Yellow circles included to highlight region of focus for 
variants with high proteolytic stability. 
 
As expected, high levels of degradation were observed in the less stable variant, 
K13L, compared to K11RK17R, which is indicated by a lower mean intensity of C-
Myc in Q2 (HA+/C-Myc+) in the presence of Sap2 and Sap9 (Table 2.3). 
Additionally, a more drastic left-ward shift is present for K13L, resulting in a higher 
percentage of events in the Q1 (HA+/C-Myc-). Therefore, the proteolytic stability 
properties of both peptides are conserved in the yeast surface display fusion and agree 
with prior degradation findings observed with purified peptide [53]. A high activity of 

















between Sap9 and Sap2 indicated by a proportion of cells within Q1, which is in-line 
with prior findings [53]. 
Table 2.3: Raw Preliminary Degradation Profile Data for Quadrants Q1 and Q2 
Peptide Sap Q1 (HA+/Myc-)* Q2 (HA+/Myc+)* 
HA C-Myc HA C-Myc 
K11RK17R NA 2618 ± 1833 149 ± 83.8 83904 ± 60119 31919 ± 38892 
2 2653 ± 1975 144 ± 85.8 81078 ± 58748 32579 ± 39243 
9 2788 ± 2018 143 ± 85.2 75025 ± 63224 22621 ± 32029 
K13L NA 3247 ± 2403 133 ± 84.7 81110 ± 56314 3979 ± 3993 
2 3413 ± 2807 141 ± 84 86589 ± 68916 4339 ± 5401 
9 3255 ± 2580 138 ± 83.9 68542 ± 55095 3170 ± 3333 
*Values represent the average of three biological replicates ± the standard deviation 
in the population (n=3). 
 
While these findings did agree with initial expectations, a larger contrast between 
variants with high and low proteolytic stability was desired for the enrichment of 
novel variants with superior stability. Therefore, optimization of the degradation 
conditions was performed to increase the contrast between K11RK17R and K13L.  
2.3.5 pH Optimization of Proteolytic Degradation 
As a first round of optimization, the role of pH was investigated on the 
activity of both Sap2 and Sap9 to degrade K11RK17R and K13L. A literature search 
found that the optimal conditions for Sap2 activity were commonly observed at pH 










Table 2.4: Reported Conditions for Optimum Activity of Saps 2 and 9 
Sap Reported Optimum pH Buffer Conditions Source 
2 4.0 100 mM citric acid [52] 
2 4.0 10 mM acetate [73] 
2 3.5 50 mM Na citrate [70] 
2 4.0 50 mM Na citrate [51] 
2 3.2-3.5 50 mM Na citrate [49] 
9 5.0 10 mM acetate [73] 
9 5.5 50 mM Na citrate [51] 
 
Due to the more common usage of citrate buffer over acetate or sodium 
phosphate buffer, the degradation of both Saps at new conditions of pH 4.0 in 10 mM 
sodium citrate for Sap2 and pH 5.0 in 10 mM sodium citrate for Sap9 was conducted. 
The resolution of these degradation profiles was compared to those obtained with the 
original conditions of 1mM NaPB. Degradation for both Saps was performed on 
K11RK17R and K13L for 2 h at 30°C in both the original and new conditions and the 
analysis was performed by flow cytometry with gating for the positive C-Myc signal, 
which would indicate the presence of the full fusion (Figure 2.6).  
 
Figure 2.6: Influence of pH on Degraded with Sap2 and Sap9. K11RK17R (a) and 
K13L (b) are displayed with C-Myc (Alexa-Flour 647 antibody) positive, 
corresponding to the presence of the full fusion protein, and C-Myc negative, 
corresponding to degraded fusion protein, proportions for a single biological replicate 
(n=1). Degradation at pH 4 and 5 was performed in 10 mM citrate buffer and 





































































 Degradation at lower pH resulted in a small increase in the degradation of 
both K11RK17R and K13L, which is observed by comparing the percentage of 
events gated for positive C-Myc signal (Figure 2.6). Comparing the mean C-Myc 
signal in the positively expressing cells showed a decrease in the C-Myc signal for 
K11RK17R for both Sap2 and Sap9 with similar variability in populations at reduced 
pH, indicating that 10 mM citrate buffer encouraged enhanced degradation (Supp. 
Table A.1). The opposite trend, with decreasing pH resulting in an increased mean C-
Myc signal, was observed for K13L with both Sap2 and Sap9. However, the standard 
deviation of K13L positively expressing the fusion was doubled in 10 mM citrate 
buffer, indicating that the observed decrease in degradation was due to a more 
heterogeneous treatment of each yeast cell. Comparing the pH of the degradation 
conditions before and after incubation demonstrated that sodium citrate did a better 
job of maintaining the pH than the NaPB did. Therefore, 10 mM citrate buffer at pH 4 
or 5 for Sap 2 and Sap9, respectively, were accepted for later optimization 
experiments for better maintenance of degradation conditions.  
2.3.6 Scale Down Analysis 
In anticipation of the large number of samples and reagent resources required 
to optimize for temperature and time of incubation, investigation into scaling down 
the degradation conditions was performed. This was examined at the previously used 
Sap concentration (200 µg/L) with both 4 x 106 cells and a reduced cell count of 2 x 
106. To also see if increasing the concentration of Saps could significantly increase 
the degradation, a higher concentration of Saps was analyzed in parallel (1000 





Sap2 due to its inferior degradation of both K11RK17R and K13L compared to Sap9 
in the preliminary degradation study (Figure 2.7).  All degradation experiments were 
performed in 10 mM citrate buffer at pH 4.0 for 2 h at 30°C.  Analysis was performed 
by comparing the percent of events in both quadrants Q1 (HA+/Myc-) and Q2 
(HA+/Myc+) resulting from either incubation condition.  
 
Figure 2.7: Degradation of Histatin 5 with High and Normal Sap2 Proportions. 
All presented data corresponds to the average of three independent biological 
replicates (n=3) with error bars indicating the standard deviation of the populations. 
Data labels on the x-axis correspond to the observed quadrants with Q1 (HA+/Myc-) 
indicating cells with positive HA (Alexa-Flour 488 antibody) signal and negative C-
Myc (Alexa-Flour 647 antibody) signal and Q2 (HA+/Myc+) indicating cells with 
positive HA and C-Myc signals. Legend denotes populations of “cell count, Sap2 
concentration in µg/mL.” No significant difference was identified in the comparison 
between all pairs of conditions.  
 
 Neither scaling down the number of cells nor increasing the amount of present 
Sap2 resulted in an increase in the degradation of histatin 5 (Figure 2.7). However, a 
significant decrease in the mean C-Myc signal from 8149 ± 21876 to 4462 ± 14168 in 
Q2 was observed between 4 x 106 cells with 200 µg/mL of Sap2 and 2 x 106 cells 





degradation of the fusion is achieved by increasing the ratio of Sap2 to cells. 
Therefore, future degradation optimization was performed at 2 x 106 cells with 1000 
µg/mL of Saps to encourage efficacious interrogation of the expressed fusion protein.  
To verify that neither the addition of Saps nor the incubation conditions 
significantly reduced the number of viable cells, viability analysis was also 
performed. Cell viability is important in this case as only live cells can be isolated and 
replicated from a peptide library. Therefore, it is important to avoid conditions that 
significantly reduce the number of variants that can be screened to preserve the size 
of a given peptide library. 
 
 
Figure 2.8: Viability Analysis of Scale-Down Conditions. All presented data 
corresponds to the average of three independent biological replicates (n=3) measured 
by a single measurement with error bars indicating the standard deviation of the 
populations. Data labels in the legend correspond to the number of cells in either 
condition. No significant difference was identified in the comparison between all 
pairs of conditions. 
 
 No significant influence of degradation conditions or Sap2 proportions was 






















and increasing the Sap2 concentration can be used without significantly reducing the 
library size. While each condition exhibited a large variance, this was attributed to the 
lack of replicate measurements taken for each biologically independent sample. This 
was addressed in later experiments by taking triplicate measurements within a sample 
at each condition for viability analysis.  
2.3.7 Optimization of Time and Temperature 
The influence of both time and temperature on the degradation of the histatin 
5 fusion was performed in parallel to identify optimal conditions for degradation. To 
examine the influence of these parameters, a cell count of 2 x 106 and a Sap2 
concentration of 1000 µg/mL was used at 30°C and 37°C for durations of 2, 4, and 6 
h. This analysis was performed using flow cytometry and by comparing the resulting 
proportions of events in quadrants Q1, corresponding to degraded peptide, and Q2, 
corresponding to intact peptide. 
 
 
Figure 2.9: Degradation of Histatin 5 as a Function of Time and Temperature. 
Degradation performed at 30°C (a) and 37°C (b) are presented. All presented data 
corresponds to the average of three independent biological replicates (n=3) with error 
bars indicating the standard deviation of the populations. Data labels in the legend 
correspond to the observed quadrants with Q2 (HA+/Myc+) indicating cells with 
positive HA (Alexa-Flour 488 antibody) and C-Myc (Alexa-Flour 647 antibody) 
signals and Q1 (HA+/Myc-) indicating cells with positive HA signal and negative C-
Myc signal. Time was not found to have a significant influence on the Q1 




















































 Comparison of the proportions present in either quadrant of interest did not 
yield a significant increase in degradation of histatin 5 with increasing time of 
incubation at 30°C and 37°C (Figure 2.9). The same was also observed for the 
influence of temperature on the degradation of histatin 5 at all observed time points 
(Figure 2.10). However, a decrease in the mean C-Myc signal in Q2 was observed 
with increasing time of incubation from 4323 ± 13611 at the original conditions of 2 
h and 30°C to 2136 ± 12012 and 2877 ± 9159 at 6 h for 30°C and 37°C, respectively 
(Supp. Table A.3). Therefore, partial degradation of the expressed fusions per cell is 
primarily observed here as was observed in previous optimization experiments. 
Increasing the degradation of histatin 5 from 2 h to 6 h also resulted in a significant 
decrease in the variability of the C-Myc signal, indicating that more homogenous 
degradation was accomplished at longer incubation times. Therefore, degradation of 
histatin 5 for 6 h at 30°C was chosen as the time and temperature to perform 
subsequent experiments on the degradation of K11RK17R and K13L.  
 
Figure 2.10: Influence of Temperature and Time on Histatin 5 Degradation. Data 
correspond to the average of Q1 (HA+/Myc-) events from three independent 
biological replicates (n=3) with error bars indicating the standard deviation of the 
populations. Data was obtained using flow cytometry. No statistical significance was 
observed between temperatures at each time point (ns).  


























 The effect of the temperature and time on viability analysis was evaluated 
with triplicate measurements for each replicate to better capture the true variability in 
the cell count of each sample. No significant difference in the cell count was observed 
between incubation temperatures and times up to 6 h (Figure 2.11). Therefore, final 
degradation at 6 h and 30°C should not limit the size of the library that can be tested 
and can be used for the final degradation analysis. 
 
Figure 2.11: Viability Analysis for Optimization of Degradation Time and 
Temperature. All presented data corresponds to the average from three independent 
biological replicates (n=3) with error bars indicating the standard deviation of the 
populations. Triplicate measurements were taken for each biological replicate. No 
statistical significance was observed between cell count at any temperature or time 
(ns). 
2.3.8 Degradation of K13L and K11RK17R 
After optimizing the pH, proportion of cells to Saps, time, and temperature of 
the degradation conditions for histatin 5 with Sap2, degradation profiles were 
gathered for K11RK17R, K13L, and histatin 5 to re-assess the resolution between 
variants with variable proteolytic stability. Degradation was performed using the 
previously identified conditions of 2 x 106 cells with 1000 µg/mL of Sap2 or Sap9 at 






















30°C for 6 h in 10 mM citrate buffer at pH 4.0 for Sap2 and pH 5.0 for Sap9 were 
analyzed using flow cytometry (Figure 2.12). 
 
Figure 2.12: Degradation Profiles. Bivariate plots are plotted for degradation of 
histatin 5, K11RK17R, and K13L without Saps and with Sap2 and Sap9. The HA 
signal is produced by the Alexa-Flour 647 antibody while C-Myc is produced by the 
Alexa-Flour 488 antibody. Percent of events within each quadrant are displayed in 
each corner with Q1 pertaining to the top-left, Q2 for the top-right, Q3 for the 
bottom-right, and Q4 for the bottom-left. Each dot represents a single cell with the 
density of cells being plotted in as a heat map. Yellow circles included to highlight 
region of focus for variants with high proteolytic stability. 
 
 From the bivariate plots, a visible difference in the degradation profiles 




















still be visible at high C-Myc signal for K11RK17R, there are almost no events 
present in this location for K13L after degradation with both Sap2 or Sap9. Therefore, 
isolating variants with high proteolytic stability over those with lower proteolytic 
stability should be possible at these degradation conditions. Compared to the original 
degradation conditions, an overall reduction in the C-Myc signal of cells expressed in 
Q2 is observed (Figure 2.12), indicating that higher levels of degradation are 
observed under optimal degradation conditions. A significant decrease in the 
variability of the C-Myc signal for K11RK17R degraded by Sap2 is also observed by 
performing degradation under the new optimum conditions (Figure 2.13). Therefore, 
a more homogenous degradation activity compared to that performed under the 
original degradation conditions can be obtained, improving the stringency of this 









Figure 2.13: Comparison of C-Myc Signal in Positively Expressing Cells Before 
and After Optimization. All presented data corresponds to the average from one 
independent biological replicate (n=1) with error bars indicating the standard 
deviation of each sample. No statistical analysis was conducted to compare means 
since only one replicate was performed for both conditions. 
 
The degradation behavior observed in the samples without Sap addition do not 
follow the same left-ward shift observed in the Sap9 and Sap2 samples (Figure 2.12). 
This is because these are incubated on ice for extended periods of time before being 
analyzed by flow cytometry in parallel with the Sap degraded samples, reducing the 
number of live cells that positively express the fusion. This is visible in the larger Q4 
(HA-/Myc-) populations, which display no fusion protein. Therefore, the comparison 
in Q1 (HA+/Myc-) to Q2 (HA+/Myc+) populations between K11RK17R, histatin5, 
and K13L tell more about the stability of the peptide in solution with K11RK17R 














































  The peptides histatin 5, K11RK17R, and K13L were shown to be 
successfully integrated into the yeast surface display system with Western blotting. 
This ensures that other antifungal peptides can be easily integrated into this system as 
well for screening, which will be important for improving the fitness of the 
protein/peptide of interest. Furthermore, it was demonstrated in this chapter that 
histatin 5 as well as K11RK17R and K13L can be degraded by Saps while expressed 
in a fusion protein. This is valuable as it indicates that proteolytic stability can be 
assessed using this yeast surface display system. Therefore, histatin 5 can be 
engineered for improved proteolytic stability to Sap2 and Sap9 as well as other Saps 
or proteases of interest as needed. 
Optimizing the degradation conditions of the yeast surface display containing the 
histatin 5 with Sap2 resulted in an increase in the degradation of all displayed fusion 
peptides. This observation was supported by comparison of the original degradation 
conditions in 1 mM NaPB at pH 7 with 200 µg/mL and 30°C for 2 h with the final 
conditions of 10 mM citrate buffer with 1000 µg/mL of Sap2 at pH 4.0 or Sap9 at pH 
5.0 and 30°C for 6 h. Overall, an increase in the resolution between the degradation 
profiles of K11RK17R and K13L was observed, allowing for the isolation of variants 
with superior proteolytic stability when screening a library of peptides. Additionally, 
is it likely that several rounds of enrichment with FACS can ensure that sufficient 
segregation is accomplished between mutants with desired proteolytic stability and 





In general, while increased resolution was accomplished in this study, a higher 
degree of contrast is desired. Given that all viability assessments showed no 
significant difference between the conditions tested as a part of optimization, more 
stringent conditions could be tested in later experiments to increase the degradation 
pressure on the displayed peptides. This could be accomplished by increasing the 
incubation time with Saps beyond 6 h, to allow for more time for peptide 
interrogation by Saps, or by increasing the ratio of Saps to yeast cells, increasing the 






Chapter 3: Incorporating Antifungal Peptides into 
Polyelectrolyte Multilayer Films (PEMs) 
 
3.1 Introduction 
Adherence of C. albicans and maturation of biofilms on or within new 
medical devices introduced to the body, such as catheters [74, 75], wound dressings 
[74, 75], prosthetics [74], and orthopedic implants [75, 76], are both a financial and 
medical concern. Caused by fungal and bacterial pathogens, these hospital-acquired 
infections represent one of the most serious complications that can arise post-surgery 
or critical care [75]. Biofilms are responsible for approximately 64% of all bacterial 
and fungal hospital-acquired infections, and the prevention of these infections 
remains a key concern not only for those susceptible to candidiasis but bacterial 
infection as well [76]. In response to this, the application of polyelectrolyte multilayer 
films (PEMs) to the surfaces of medical devices represents a promising solution that 
can be used to mitigate both bacterial and fungal infections in vivo [75, 76].  
PEMs consist of alternating layers of polycationic and polyanionic species 
that can be sequentially deposited onto a substrate of choice through layer-by-layer 
(LBL) deposition [77, 78]. LBL deposition involves the serial dipping of the substrate 
in premade polyelectrolyte and drug solutions, each followed by washing steps, to 
coat the coat the substrate surface in a multilayer film. An illustration of this process 









Figure 3.1: Illustration of PEM Film Generation by Layer-By-Layer (LBL) 
Deposition. Figure republished with permission of Royal Society of Chemistry, from 
[78]; permission conveyed through Copyright Clearance Center, Inc. LBL deposition 
is performed by serially soaking the negatively charged substrate surface with 
alternating solutions of polycation and polyanion to establish a polyelectrolyte 
multilayer film composed of repeating polycation/polyanion bilayers. 
 
Additionally, PEMs can incorporate drugs that provide contact and slow-
release antifungal and antibacterial action, reducing the risk of infection, which is 
illustrated in Figure 3.2 [75, 76, 77]. Therefore, PEMs can prevent the initial 
adherence and subsequent infection of bacterial and fungal pathogens. 
 
 
Figure 3.2: Illustration of the Antimicrobial/Antifungal Action of Drug-Loaded 
PEMs. Figure was reproduced from reference with permission from ACS [75]. 
Polyelectrolyte multilayer films prevent bacterial and fungal colonization by 
preventing initial adhesion, killing the pathogen upon contact with exposed drugs 
embedded in the PEM surface, and killing the pathogens in the surrounding 
environment as drug is slowly released over time. 








  PEMs can also be applied to a variety of substrates of various materials and 
geometries with highly tunable properties that are dependent on the polyelectrolytes 
used and the pH, ionic strength, and temperature of their solutions [75, 77, 79]. PEMs 
are also highly stable and can be stored under dehydrated conditions at ambient 
temperatures for extended periods of time until needed [78]. Given these beneficial 
properties, PEMs are highly versatile and may be engineered to prevent biofilm-
associated C. albicans infections.   
 Studies have been conducted to determine this possibility of treating C. 
albicans with drug-incorporated PEMs. For example, b-peptides were incorporated 
into a poly(L-glutamic acid)/poly(L-lysine) (PGA/PLL) film using a dipping solution 
at a concentration of 1 mg/mL and exhibited significant antifungal activity against C. 
albicans [80]. The b-peptides in this instance were released into the surrounding 
solution for up to 400 hours, resulting in a 20% reduction in cell viability after 2 h 
and a 74% reduction in metabolic activity after 7 h [80]. Additionally, these same 
PEMs were coated onto catheter tubing and obtained similar results [81]. 
Chlorhexidine has also been incorporated into PEMs composed of poly(ethyl 
methacrylate)/tetrahydrofurfuryl methacrylate at the high dose of 16.5 mg per 10 mm 
disk and reduced biofilm development by 75% and reduced metabolic activity by 
84% [82]. Given these examples, histatin 5 and the related antifungal peptide 





3.2 Materials and Methods 
3.2.1 Polyelectrolyte Multilayer Film (PEM) Fabrication 
3.2.1.1 Peptides 
The peptides used in this study (Table 3.1) were commercially synthesized 
(Genscript) with ³95% purity and trifluoracetic acid salt removal by exchange to 
chloride. The lyophilized peptides were reconstituted in water and diluted in 20mM 
NaCl to the desired concentrations. 
Table 3.1: Peptides Used for Polyelectrolyte Multilayer Films 




Histatin 5 D S H A K R H H G Y K R K F H E K H H S H R G Y 3036 +12 
K11RK17R - - - - - - - - - - R - - - - - R - - - - - - - 3092 +12 
*Net charge (pH 7.0) is calculated only from the amino acid side chains and does not 
include charge from the N-terminal amine.  
**Dashes indicate unchanged amino acids previously found in parent peptide.  
3.2.1.2 Polyelectrolyte Multilayer Film (PEM) Fabrication 
Silicon and quartz substrates were cut into 7 x 18 mm chips, serially cleaned 
with acetone, ethanol, methanol, and deionized water, and dried under a filtered air 
stream. Substrates were treated with oxygen plasma for 5 min using a 4000 Series 
Branson Barrel Resist Stripper (Branson International Plasma Corporation) to impart 
negative charge on the surface of the substrate. Base layers were deposited onto the 
substrate surface using polyethylenimine (PEI) and sulfonated polystyrene (SPS) 
solutions. A solution of 50 mM PEI (MW = 50,000, Sigma-Aldrich) was prepared in 
25 mM NaCl and 5 mM HCl in water and was sterile filtered using a 0.22 µm filter 





in 25 mM NaCl in water and was sterile filtered using a 0.22 µm filter before use. PEI 
and SPS were deposited onto the treated substrate by (1) soaking the chip in the PEI 
solution for 5 min, (2) washing the chip twice by soaking in water for 1 min per wash, 
(3) soaking the chip in the SPS solution for 5 min, and (4) washing the chip twice by 
soaking in water as before. Steps (1) through (4) were repeated until 10 PEI/SPS 
bilayers were formed. The fabrication of these PEI/SPS base layers was performed on 
a DR3 dipping robot (Reigler & Kirstein GmbH). Following fabrication, the 
substrates were dried under a filtered air stream. 
Peptides were deposited onto the base layers by incorporating a step of dipping 
into a peptide solution between dipping in the poly-L-glutamic acid and poly-L-lysine 
polymer solutions. Solutions of poly-L-glutamic acid sodium salt (PGA, MW = 
50,000 – 100,000 for experiments with quartz and >50,000 for the experiments with 
silicon, Sigma-Aldrich) and poly-L-lysine hydrobromide (PLL, MW = 15,000 – 
30,000, Sigma-Aldrich) were prepared at a concentration of 1 mg/ml in 20 mM NaCl 
in water. The peptides were diluted in 20 mM NaCl to either 1mg/ml or 3 mg/ml and 
the absorbance at 280 nm was measured prior to use. Films were fabricated by (1) 
soaking the chip in the PGA solution for 5 min, (2) washing the chip twice by soaking 
in water for 1 min per wash, (3) soaking the chip in the peptide solution with the 
desired concentration for 5 min, (4) washing the chip twice with water as before, (5) 
soaking the chip in the PLL solution for 5 min, and (6) washing the chip twice with 
water as before. Steps (1) through (6) were repeated until 60 trilayers (one trilayer 
consists of PGA-peptide-PLL) were formed. For control chips, water was used in 





films was performed on a DR3 dipping robot (Reigler & Kirstein GmbH). Following 
fabrication, the films were dried under a filtered air stream. The absorbance at 280 nm 
of the quartz chips as well as the solutions was measured after centrifuging at 15,000 
xg for 5 min.  
3.2.1.3 Thickness Characterization 
Film thickness was characterized for silicon substrates post-fabrication. The 
measurements were performed by an LSE Model Gaertner Ellipsometer (Gaertner 
Scientific Corporation) with an incidence angle of 70°. Five measurements were 
taken along the center of each chip and were averaged to approximate the overall 
thickness of the film on the substrate.  
3.2.2 Biofilm Inhibition Assays 
3.2.2.1 Strains and Culture Conditions 
The fungal pathogen C. albicans strain ATCC90028 was purchased from the 
American Type Culture Collection (ATCC). Cells were first inoculated from a yeast-
peptone-dextrose (YPD) agar (10 g/L yeast extract, 20 g/L peptone, 20 g/L glucose, 
2% (w/v) agar) plate into 8 mL of YPD liquid medium and grown overnight (»16 h) 
at 30°C while shaking at 230 rpm. The overnight cell culture was subsequently 
subcultured into 25 mL of fresh liquid YPD at a starting OD600 of 0.1. The culture 
was grown at 30°C while shaking at 230 rpm until mid-log growth phase (»3.5-4 h 
with an OD600 of »1.0). An aliquot of 107 cells was centrifuged at 2,000 rpm for 5 
min and the liquid was discarded. The cell pellet was washed 3 times with PBS (8 g/L 





resuspended in 50% RPMI 1640 media (5.2 g/L RPMI 1640, 17.265 g/L MOPS, pH 
7.0 ± 0.1) in water to 5 x 105 cells/mL.  
3.2.2.2 C. albicans Seeding and Biofilm Formation 
Chips coated using either 0, 1, or 3 mg/ml of either peptide in Table 3.1 were 
placed in individual wells of Nunc® Lab-Tek® II coverglass-bottomed, 4-well 
chamber slides. The C. albicans cell suspension was added to each well containing a 
chip, and 50% RPMI 1640 media (Gibco) was added to the remaining empty well as 
sterility control (500 µl/well). The chamber slide was sealed with parafilm and 
incubated at 37°C for 2 h to allow C. albicans to adhere to the film surfaces.  
After 2 h, chips were transferred to a new chamber slide cassette after gently 
washing with PBS and fresh 50% RPMI 1640 media was added to each chip (500 
µl/well). The entirety of the media control was transferred to an unoccupied well on 
the new cassette. The new cassette was sealed with parafilm and incubated at 37°C. 
Chamber slides were momentarily removed at 6, 12, and 18 h and finally removed at 
24 h for microscopy analysis followed by growth inhibition characterization and a 
final round of microscopy.  
3.2.2.3 Microscopy  
Microscopy characterization of quartz chips was conducted using an Olympus 
IX83 microscope at 6, 12, 18, and 24 h after seeding. At each time point, a minimum 
of 3 images were taken at random locations over the top face of the substrate using a 





Microscope characterization of silicon chips was conducted using a Zeiss 
AX10 microscope after 24 h of growth. A minimum of 3 images were taken at 
random locations over the top face of the substrate using bright field (BF) and dark 
field (DF) filters using a 10x objective.  
3.2.2.4 Quantification of Growth Inhibition 
The capability of the various peptide-loaded films to inhibit fungal growth 
was quantitatively assessed using 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT), which is reduced to a water-soluble dye by 
metabolically active cells. Chips were first gently transferred to a new chamber slide 
cassette. An XTT solution (0.5 g/L XTT in PBS, 1 µM menadione) was added to all 
occupied wells (675 µl/well), and the cassettes were sealed with parafilm and 
incubated at 37°C for 2 h. The liquid was collected and centrifuged at 2,000 rpm for 5 
min and was aliquoted into 5 individual wells of a 96-well plate (100 µl/well). 
Absorbance at 490, the absorbance maximum for the water-soluble dye resulting from 
XTT reduction, and 600 nm was measured using a 96-well plate reader (BioTek) to 
quantify the reduced XTT and any cell contamination respectively. Growth inhibition 
was calculated using from the absorbance of the XTT product in the sterility control 
(A"#$%&&), the PEM embedded with peptide (A"#$
'(')*+(), the PEM without peptide 
(A"#$
,-	'(')*+(), and the background absorbance signal (A"#$) with the following 
equation: 










A one-way ANOVA or two-way ANOVA analysis followed by Tukey’s 
multiple comparisons test (GraphPad Prism 8.01) was performed to statistically 
assess the impact of the drug-loaded PEMs on the reduction in metabolic activity of 
C. albicans. 
3.3 Results 
3.3.1 Scope of Research 
Polyelectrolyte multilayer films (PEMs) were embedded with the peptides 
histatin 5 and K11RK17R (Table 3.1) were fabricated to assess their capability at 
preventing fungal adhesion and biofilm growth. The PEMs were fabricated via layer-
by-layer deposition using 0, 1, and 3 mg/mL dipping solutions for each peptide and 
were tested in parallel with the same cell culture of C. albicans. These experiments 
were performed to explore potential routes of therapeutic administration for treating 
topical candidiasis.  
3.3.2 Characterizing Film Thickness in Silicon Substrates 
Thickness characterization was performed on all PEMs after fabrication to 
determine the approximate amount of peptide loaded onto each chip and the 
contribution of peptide to the thickness of the film. From these measurements, histatin 
5 was shown to increase the thickness of the PEMs, adding approximately 45.85 ± 
23.77 nm to the overall thickness of each chip. A lack of statistical significance 
between the thickness of the PEMs constructed using 1 mg/mL and 3 mg/mL dipping 
solutions of histatin 5 was also observed (Figure 3.3), indicating the thickness is not 






Figure 3.3: Thickness of Silicon Substrates with Films Post-Fabrication. All 
measurements displayed represents the average thickness with error bars 
corresponding to the standard deviation (n=3 chips). One-way ANOVA shows no 
statistically significant difference between 3 mg/mL and 1 mg/mL loading (ns) while 
a significant difference exists between films without histatin 5 (0 mg/mL) and those 
with histatin 5. The number of asterisks indicates the level of significance: * for 
P<0.1.  
3.3.3 Biofilm Inhibition on Silicon Substrates 
The ability of histatin 5-loaded PEMs to prevent C. albicans adhesion and 
proliferation was tested to determine if the fabricated PEMs on silicon substrates were 
efficacious.  To assess this, chips with films fabricated using 0, 1, and 3 mg/mL of 
histatin 5 were incubated with C. albicans for 24 h. Following incubation, both 
microscopy analysis and quantification of growth inhibition was conducted. 
3.3.3.1 Microscopy Analysis of Silicon Substrates 
Microscopy was performed to analyze the relative amounts of fungal adhesion 



























Figure 3.4: Microscope Images of Silicon Substrate PEMs. Images (a) – (c) 
correspond to silicon substrates dosed with 0, 1, and 3 mg/ml histatin 5 for the first 
trial. Images (d) – (f) correspond to silicon substrates dosed with 0, 1, and 3 mg/mL 
histatin 5 for the second trial. All presented images were taken with bright field 
objective and have scale bars equivalent to 100 µm.  
 
No significant difference is visible in the adhesion or viability profiles as a 
function of histatin 5 concentration in the first trial, though there is a distinguishable 
increase in the presence of C. albicans yeast cells and hyphae in the peptide-loaded 
chips compared to the control in the second trial. The growth appears to be inversely 
proportional to peptide concentration, which was unexpected due to the well-
established fungicidal activity of histatin 5.  
3.3.3.2 Quantification of Growth Inhibition in Silicon Substrates 
To validate the conclusions reached by microscopy analysis, quantitative 
viability analysis was performed with XTT to determine the relative metabolic 
activity of C. albicans on the surface of each chip (Figure 3.5). The metabolic activity 
of C. albicans in the supernatant was also measured as a precaution to help explain 
the findings observed with adherent cells and identify potential sources of error in the 
(a) (b) (c)





experiment (Figure 3.6). From this analysis, the inverse concentration dependence 
was confirmed in both trials with significant differences in the relative metabolic 
activity of adherent C. albicans on the surface of either chip.  
 
Figure 3.5: XTT Data for Growth on Silicon Substrates. (a) A490 absorbance 
measurements gathered from the first trial of PEM chips after 24 h of incubation and 
(b) A490 absorbance measurements gathered from the second trial of PEM chips after 
24 h of incubation. All measurements displayed represent the average XTT signal for 
a single chip with error bars corresponding to the standard deviation (n=5). One-way 
ANOVA was performed to determine that the A490 signal increased with histatin 5 
concentration. The number of asterisks indicates the level of significance: **** for 
P<0.0001.  
 
Additionally, no significant differences in the metabolic activity of the 
supernatant was observed in the first trial (Figure 3.6a). This indicates that equivalent 
cellular viability is present in the supernatant of each PEM and that any peptide that 
diffused into the supernatant during incubation did not have a significant antifungal 
effect. Combine with the silicon substrate surface analysis, this indicates that 
integration of histatin 5 increased the biofilm growth on the surface of the chip and 
did not have a significant effect on preventing cellular adhesion.  
 This correlation was also present in the comparison between chips 





































3.5b). However, the control chip had significantly less metabolic activity in its 
supernatant, which could be indicative of a lower level of initial cell seeding on the 
surface or due to less release of cells into the supernatant from the surface or biofilm.   
 
Figure 3.6: XTT Data for Silicon Chip Supernatants. (a) A490 absorbance 
measurements gathered from the supernatants of PEM chips in the first trial after 24 h 
of incubation and (b) A490 absorbance measurements gathered from the supernatants 
of PEM chips in the second trial after 24 h of incubation. All measurements displayed 
represent the average XTT signal for a single chip’s supernatant with error bars 
corresponding to the standard deviation (n=5). One-way ANOVA was performed to 
determine that there was no statistically significant difference between the 
supernatant of all chips in the first trial (ns) and a statistically lower A490 signal in the 
control chip compared to the histatin 5 loaded chips in the second trial. The number 
of asterisks indicates the level of significance: *** for P<0.001. 
  
To quantify and compare the capability of either peptide to inhibit the growth 
of C. albicans biofilms, the reduction in the metabolic activity can be used as a metric 
of comparison. Direct comparison of the capacity of each PEM to reduce the 
metabolic activity of the adherent C. albicans population was investigated within 
each independent trial (Figure 3.7). In both cases, the presence of peptide resulted in 
an increase in the metabolic activity of the adherent C. albicans with higher increases 



































Figure 3.7: Reduction in Metabolic Activity for Silicon PEMs. (a) Reduction in 
metabolic activity calculated from the PEM chips in the first trial after 24 h of 
incubation and (b) reduction in metabolic activity calculated from the PEM chips in 
the second trial after 24 h of incubation. All measurements displayed represents the 
average reduction in metabolic activity based on that of a single chip with error bars 
corresponding to the standard deviation (n=5). A negative reduction in metabolic 
activity corresponds to an increase in biofilm growth. One-way ANOVA was 
performed to identify a significantly lower reduction in metabolic activity in the 3 
mg/mL chip of the first trial compared to the 1 mg/mL chip and no significant 
difference in metabolic activity reduction in the second trial between the two chips 
(ns). The number of asterisks indicates the level of significance: ** for P<0.01. 
3.3.4 Biofilm Inhibition on Quartz Substrates 
Although experiments on silicon substrates provided initial evidence that 
incorporating histatin 5 has an effect on C. albicans growth, subsequent experiments 
were performed on quartz substrates for ease in microscopy analysis and to allow the 
acquisition of higher magnification images. PEMs were constructed in an identical 
manner to that performed with silicon substrates for this set of experiments. The 
peptide K11RK17R, which has a higher antifungal activity against C. albicans 
compared to histatin 5 [53], was also investigated in parallel to histatin 5 in these 
experiments to compare its biofilm inhibition performance. An initial 2 h seeding 
phase at 37°C was implemented to allow for sufficient surface adhesion and to more 

























































the metabolic activity of adherent cells. Following the seeding phase, chips were 
incubated at 37°C and removed at 6, 12, and 24 h to characterize the extent of biofilm 
proliferation and metabolic activity reduction due to the integration of either histatin 5 
or K11RK17R in the PEM.  
3.3.4.1 Microscopy Analysis of Quartz Substrates 
Microscopy analysis was conducted for quartz substrates to assess the 
agreement of observations associated with histatin 5-loaded PEMs on silicon 
substrates with those on quartz substrates and to assess the ability of K11RK17R to 
prevent fungal adhesion and proliferation (Figure 3.8).  In all cases, the qualitive 
comparison of performance on quartz substrates was much easier to discern due to the 
implementation of the initial seeding period. However, at 24 h, the imaging of these 
films became more difficult to perform due to the growth cell clumps in the 
supernatant, which cast a dark shadow on the surface of the substrate.     
With regards to the histatin 5-loaded PEMs, an identical trend was observed 
here as was observed with the silicon substrates. In all cases, large, numerous biofilm 
networks are visible after 24 h regardless of the presence of histatin 5 in 1mg/mL or 3 
mg/mL concentrations. Additionally, a visible difference in biofilm growth after only 
6 h of incubation is present, indicating that histatin 5 may actually help in fungal 
colonization of the surface. This supports the previous silicon substrate findings and 
suggests that the integration of histatin 5 into PEMs can actually have a detrimental 


































































































































































































































































































































































































































Meanwhile, K11RK17R exhibits efficient reduction of fungal growth on the 
surface, with only a small fraction of the present cells existing in the hyphal state after 
24 h of incubation. This behavior is significant because the transition of C. albicans 
from yeast to hyphal states is a major virulence factor, which assists in the invasion of 
endothelial cells and in infection [78]. While some hyphal networks are visible on the 
PEMs fabricated with 1 mg/mL K11RK17R, these are still very small in comparison 
to the size of the networks observed on the control chips.  
3.3.4.2 Quantification of Growth Inhibition in Quartz Substrates 
The ability of K11RK17R and histatin 5 to inhibit C. albicans growth was 
quantified through XTT analysis and comparison in reduction of metabolic activity in 
an identical fashion to that performed with silicon substrates. In the case of histatin 5, 
PEMs that incorporate the peptide at 1 mg/mL are shown to reduce the metabolic 
activity of the cells in solution after 6 and 24 h of incubation (Figure 3.9a). 
Meanwhile, incorporating histatin 5 at 3mg/mL increases the metabolic activity of the 
cells after 6 and 24 h. The opposite is observed for PEMs constructed with 
K11RK17R with no significant difference in the reduction of metabolic activity 
between 6 and 24 h (Figure 3.9b). This indicates that there is a dose response present 
in for the treatment of C. albicans biofilms for histatin 5 with high concentrations 
significantly encouraging biofilm growth, which was also observed on silicon 
substrates. For K11RK17R, an opposite dose response is observed with high 
concentrations of K11RK17R reducing biofilm growth. Because there is no 





mg/mL and 3 mg/mL peptide, this indicates that these PEMs could continue to 
display similar performance in preventing biofilm formation after 24 h. 
At 12 h the growth of biofilms on the surface of both K11RK17R and histatin 
5 PEMs is significantly increased. This observation was made for a single biological 
replicate. Therefore, this does not confidently reflect the actual biofilm growth 
behavior of PEMs that were incubated for longer durations. While these observations 
do agree with the microscopy analysis for histatin 5 more so than that for 
K11RK17R, the large increase in metabolic activity is likely due to the large variance 
in A490 signal present at this time point, which translates to a large magnitude in cell 
growth (Supp. Figure B.1). Alternatively, the significantly high viability in the 
supernatant and on the chip at 12 h could indicate that the stability of the PEM is 
compromised between 12 and 24 h at 30°C. This would result in the release of 
peptide and adherent C. albicans into the supernatant, decreasing the metabolic 
activity observed on the surface of the PEMs and reducing supernatant viability 















Figure 3.9: Reduction in Metabolic Activity in Histatin 5 and K11RK17R-
Loaded Quart Chips. Reduction in metabolic activity calculated from histatin 5 (a) 
and K11RK17R-loaded (b) PEM chips fabricated on quartz substrate at 6, 12, and 24 
h. All measurements displayed represents the average reduction in metabolic activity 
based on that of a single, individual chip for 6 and 12 h (n=1) and two chips for 24 h 
(n=2) with error bars corresponding to the standard deviation. A negative reduction in 
metabolic reduction corresponds to an increase in biofilm growth. The number of 
asterisks indicates the level of significance: * for P<0.01 and **** for P<0.0001. 
 
  Comparing the endpoint capability of histatin 5 and K11RK17R PEMs to 
prevent colonization and biofilm growth after 24 h of incubation, a stark difference in 
metabolic activity is observed (Figure 3.10). For example, high concentrations of 
histatin 5 can significantly help encourage biofilm growth. These observations are 
supported by microscopy analysis for the comparison of the control (Figure 3.8k) and 
3 mg/mL film (Figure 3.8.m), which show more extensive biofilm growth on the 3 
mg/mL substrate compared to the control. The reduction in metabolic activity 
demonstrated in the XTT analysis by the 1 mg/mL histatin 5 substrate (Figure 3.8l) is 
difficult to validate with microscopy as both chips show approximately equivalent 
biofilm growth.  Meanwhile, the high concentrations of K11RK17R embedded in 
PEMs results in a significant increase in metabolic reduction. This is supported by 
microscopy analysis as significantly more biofilm growth is visible on the control 







































































case of the 1 mg/mL K11RK17R substrate (Figure 3.8n), findings from the XTT 
analysis contradict with microscopy findings. This is reconciled by the large variance 
in the calculated reduction of metabolic activity for this sample, which suggests that 
the inhibition of biofilm formation is minimal in comparison to the control. In 
general, this indicates that the K11R and K17R mutations initially found to improve 
the proteolytic stability of histatin 5 may also provide additional fitness advantages 
for the incorporation into polyelectrolyte multilayer films with dipping solutions at 
high concentrations of peptide.  
 
 
Figure 3.10: Endpoint Reduction in Metabolic Activity. (a) Reduction in metabolic 
activity calculated from the quartz, histatin 5-loaded PEM chips after 24 h of 
incubation and (b) reduction in metabolic activity calculated from the quartz, 
K11RK17R-loaded PEM chips after 24 h of incubation. All measurements displayed 
represents the average reduction in metabolic activity based on that of two individual 
chips with error bars corresponding to the standard deviation (n=2). A negative 
reduction in metabolic reduction corresponds to an increase in biofilm growth. One-
way ANOVA was performed to determine that higher concentrations of histatin 5 
correlate to a lower reduction in metabolic activity while the opposite is true for 
K11RK17R. The number of asterisks indicates the level of significance: **** for 
P<0.0001.  
3.4 Discussion 
Integration of histatin 5 in PEMs deposited on both silicon and quartz substrates 


























































surface, which increased with loading peptide concentration. This observation was 
supported by both microscopy and XTT analyses. These findings were unexpected as 
prior work demonstrated that histatin 5 has antifungal properties and can be used to 
inhibit C. albicans biofilm formation [33, 40, 42, 53]. Furthermore, histatin 5 has 
been integrated into hydrogels for topical treatment of C. albicans [83]. This indicates 
that integrating histatin 5 into PEMs can significantly influence the activity of the 
peptide and that dehydrated storage of histatin 5 could have a detrimental influence 
on its antifungal activity. 
Alternatively, the unexpected observations made with respect to histatin 5 in these 
experiments could be due to errors in PEM fabrication. For example, the thickness of 
the PEMs deposited on silicon in these experiments were 10-fold thinner than those 
constructed with 60 (PGA-b-peptide-PLL)n trilayers in another study [80]. Highly 
variable loading was also observed in comparison of peptide dipping solutions before 
and after PEM fabrication (Supp. Figure B.2) as well as the A280 absorbance from 
chip-to-chip after PEM fabrication (Supp Figure B.3). Therefore, it is likely that 
insufficient amounts of histatin 5 was loaded onto each chip during fabrication, 
resulting in lower than expected antifungal activity. To verify this, stability and 
release studies should be conducted. Future works should optimize the PEM 
fabrication process to ensure peptide loading levels and film characteristics are 
consistent with expected findings. Alternatively, different polymers could be 
considered to encourage peptide integration. Since PGA/PLL PEMs are an example 
of exponentially growing films, weak electrostatic interactions exist between the 





and peptide during wash steps [75]. On the other hand, linearly growing PEMs, such 
as those produced by poly(styrenesulfonate)/poly(allylamine) (PSS/PAH)n, are 
characterized by stronger electrostatic interactions and are highly stratified and could 
be used to potentially increase peptide loading [75]. Alternatively, PGA could be 
removed from the PEM fabrication process, relying solely on the positive charge of 
the antifungal peptide to generate the polycation portion of the bilayer.  
Compared to histatin 5, K11RK17R demonstrated significantly higher biofilm 
inhibition at high concentrations, which was observed in both microscopy and XTT 
analysis. Meanwhile, PEMs prepared from 1 mg/mL of K11RK17R exhibited only 
minor biofilm inhibition at low concentrations with microscopy analysis. These 
observations were not supported by XTT analysis and are most likely due to small 
differences in A490 signal. Therefore, future work should aim to improve the XTT 
assay by increasing the seeding of C. albicans and subsequentially the contrast in 
metabolic activity between concentrations of peptide. Alternatively, increasing the 
number of replicates could lead to improved differentiation and result in more 







Chapter 4: Conclusions and Future Work 
 
4.1 Conclusion 
In Chapter 2, the antifungal peptide histatin 5 was successfully integrated into a 
yeast surface display system and was shown to be degradable by Saps 2 and 9 while 
expressed as a part of a fusion protein. It was also shown that the degradation of the 
peptide could be influenced by changing the degradation conditions including the 
proportion of protease to cells as well as the buffer, pH, temperature, and time of 
incubation. Optimization resulted in the identification of new conditions that 
improved the resolution between proteolytically stable (K11RK17R) and 
proteolytically susceptible (K13L) variants of histatin 5. Now that we have a better 
understanding of the system, further improvement can be performed to improve the 
stringency of this system. Therefore, it is promising that this system could be used to 
screen for novel variants with enhanced proteolytic stability produced using directed 
evolution.  
In Chapter 3, a study was performed where histatin 5 and the double mutant 
K11RK17R were integrated into polyelectrolyte-multilayer films (PEMs) on both 
silicon and quartz substrates and used to inhibit C. albicans biofilm formation. From 
this study, it was observed that K11RK17R could significantly reduce the metabolic 
activity of C. albicans and reduce biofilm formation after 24 h, while the opposite 
was observed for histatin 5, which increased C. albicans growth and biofilm 





improve the loading of peptide on either substrate, this study shows that the peptide 
can be successfully incorporated and potentially used to prevent infection.  
4.2 Future Work 
4.2.1 Improving the Proteolytic Stability of Histatin 5 
The yeast surface display system developed and optimized in this study can be 
used to identify novel variants of histatin 5 with improved proteolytic stability. This 
can be accomplished by using degenerate primers to introduce random mutations into 
histatin 5 at amino acid positions of interest and screening for resulting peptide with 
improved proteolytic stability using Sap2 and Sap9. Given that a significant 
improvement in the proteolytic stability of histatin 5 was imparted by K11R and 
K17R mutations, further investigation should primarily be investigated at these 
positions. The primers required to sample all amino acids at the K11 position can be 
used with the QuickChange II site-directed mutagenesis kit (Agilent) are displayed in 
Table 4.1 below. Similarly, the primers required to sample all amino acids at the K17 
position can be used with the same kit and are displayed in Table 4.2 below.  
Table 4.1: Degenerate Primers for K11 Mutagenesis 




Table 4.2: Degenerate Primers for K17 Mutagenesis 




The neighboring amino acids to K11 and K17 should also be investigated as the 





possibly preventing recognition and subsequent degradation. The mutants identified 
with enhanced proteolytic stability should then be used to treat C. albicans in an 
identical fashion to previous studies to ensure that the mutations do not compromise 
antifungal activity [53]. 
4.2.2 Alternative Methods to Improve Proteolytic Stability 
While it was shown in this study that the peptide can be expressed in a yeast 
surface display system and interrogated with Saps without significantly 
compromising the viability of the yeast cell, dosing the cells with Saps does not 
ensure that each fusion is interrogated. To mitigate this issue, the yeast endoplasmic-
reticulum sequestration screening (YESS) system can be used instead of traditional 
yeast surface display. YESS addresses this issue of adequate Sap interrogation by 
simultaneously expressing a similar yeast surface display fusion along with a protease 
using the divergent GAL1,10 promoter, which is shown in Figure 4.1 [84]. The 
additional expression of the protease ensures that the fusion protein is interrogated by 
the protease in the endoplasmic reticulum before being translocated to the cell wall, 
negating the need to supplement the cells with purified protease and significantly 
reducing the required time and resources by performing digestion during expression. 
Though originally designed to screen for proteases with enhanced activity, this 










Figure 4.1: Illustration of YESS System. Figure is modified with permission from 
[84]. Copyright 2017 American Chemical Society. A divergent galactose-inducible 
promoter (pGAL1-pGAL10) controls the expression of the substrate and protease 
library. The peptide library consists of a terminal HA tag followed by the peptide of 
interest, a FLAG epitope tag, and Aga2 protein to anchor the fusion to the cell wall 
through association with Aga1. The protease is expressed to the endoplasmic 
reticulum to interrogate the fusion during expression. Both FLAG and HA tags are 
detectable with antibodies, allowing for degradation analysis with flow cytometry and 
FACS.  
4.2.3 In Vivo Testing of Fabricated PEMs 
Given the observed improvement in biofilm inhibition observed by the PEM 
fabricated with a 3 mg/mL K11RK17R dipping solution, in vivo testing should be 
performed to progress its therapeutic development. This could be accomplished by 
depositing the K11RK17R-embedded PEMs on a disk and observing its ability to 
inhibit oral fungal infection in a mouse model, which was previously performed by 
another group using an identical PGA/PLL PEM system embedded with 
poly(methylmethacrylate) and chromofungin [85]. 
 Prior to in vivo testing, more characterization is also required for the PEMs 





these chips and the stability of the PEMs. Both of these properties are commonly 
investigated in other studies [80, 81, 86]. By studying the drug-release profile of these 
PEMs, the true endpoint at which biofilm inhibition is no longer inhibited can be 
determined. Additionally, the stability of the chip in serum, saliva, and water will 
assist in determining the stability of the chip in these environments, which may 
influence their rate of drug release. By studying both of these parameters, further 
confidence in the performance of our PEMs can be gained. 
Additionally, optimization the construction process is required for the PEMs 
investigated in this study to ensure even and sufficient drug loading from chip-to-
chip. Optimization of this process may also improve the efficacy of the histatin 5 
loaded PEMs, as their failure to inhibit biofilm formation was likely due to 
insufficient loading. Alternatively, it may be worthwhile to reduce the trilayers (PGA-
peptide-PLL)n to bilayers (Peptide-PLL)n, as removing the polycation species could 
ensure a higher loading of the peptide to the chip due to electrostatic association. In 
either case, the PEMs investigated in this study show promise for in vivo therapeutic 
application and should be further investigated as a novel treatment for the prevention 
















Appendix A – Supplemental Figures (Chapter 2) 
Table A.1: Raw Data for Influence of pH on Sap2 and Sap9 
Peptide Sap pH % Myc + 
Events 
C-Myc Signal* % Myc – 
Events 
C-Myc Signal* 
K11RK17R 2 7.0 67.26 19192 ± 26202 32.74 82.5 ± 87.2 
4.0 61.3 15343 ± 23871 38.7 85.9 ± 86 
9 7.0 65.45 21949 ± 3115 34.55 85.4 ± 87.2 
5.0 63.26 18011 ± 25488 36.74 74.5 ± 86.1 
K13L 2 7.0 71.4 2394 ± 3728 28.53 76.4 ± 7.2 
4.0 52.53 3817 ± 6108 47.47 91 ± 86.3 
9 7.0 62.99 3762 ± 5362 37.01 96.7 ± 89.9 
5.0 61.85 5380 ± 6336 38.15 91.8 ± 87.6 
* All values represent the average intensity determined from a single biological 
replicate ± the standard deviation in the population (n=1). 
 








%Events HA Signal C-Myc Signal 
2 200 8.27 ± 1.66 3447 ± 5258 133 ± 190 
1000 9.75 ± 2.68 4412 ± 7351 136 ± 175 
4 200 6.64 ± 1.61 3528 ± 6242 136 ± 197 
1000 8.18 ± 0.82 3788 ± 5750 125 ± 237 
 Q2 (HA+/Myc+)* 
%Events HA Signal C-Myc Signal 
2 200 60.67 ± 15.93 51138 ± 89422 6665 ± 18714 
 1000 62.10 ± 10.74 46786 ± 77260 4462 ± 14168 
4 200 65.27 ± 6.70 64494 ± 99633 8149 ± 21876 
 1000 65.47 ± 6.77 67879 ± 95496 5692 ± 15914 
*Values represent the average of three biological replicates ± the standard deviation 




















% Events* HA Signal* C-Myc Signal* 
0 30 66.50 ± 21.71  48121 ± 78549 6381 ± 19763 
37 59.35 ± 2.57 48859 ± 84649 5993 ± 18038 
2 30 64.70 ± 7.41 61579 ± 73232 4323 ± 13611 
37 66.67 ± 7.52  54558 ± 65604 4454 ± 13610 
4 30 63.13 ± 12.72 55254 ± 63359 3104 ± 12510 
37 67.00 ± 2.51 56514 ± 66316 3050 ± 9245 
6 30 56.70 ± 8.35 42417 ± 58393 2136 ± 12012 
37 63.1 ± 2.27 48120 ± 59457 2877 ± 9159 
*Values represent the average of three biological replicates ± the standard deviation 






Appendix B – Supplemental Figures (Chapter 3) 
 
Figure B.1: Relative A490 for Quartz PEM Supernatants. The average A490 signal, 
corresponding to that of XTT, is shown for both histatin 5 and K11RK17R-loaded 
quartz PEM chips based on a single chip at 6 h and 12 h (n=1) and two chips at 24 h 




Figure B.2: Absorbance Differences in Peptide Dipping Solutions Pre- and Post-
Fabrication. The plotted signal represents the difference in the absorbance at 280 nm 
(A280) between the peptide dipping solutions before and after centrifuging after 
fabrication. The average difference in A280, is shown calculated from n=3 chips for 









































Figure B.3: Absorbance of PEM Films Post-Fabrication. The absorbance at 280 
nm was measured for each PEM fabricated on quartz substrate with (a) histatin 5 and 
(b) K11RK17R to get an estimate of the peptide loading in a given chip. Triplicate 
measurements were performed for each chip (n=3). The data graphed represent 
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